FDA ODE IV Director Feigal to join CBER as deputy director for medicine.
FDA OFFICE OF DRUG EVALUATION IV DIRECTOR RECRUITMENT UNDER WAY to find a replacement for David Feigal, MD, who will be joining the Center for Biologics Evaluation & Research as deputy director for medicine effective Sept. 1. FDA will also have to step up its efforts to recruit a permanent director of the Division of Antiviral Drug Products: acting director Donna Freeman will be leaving the agency at the end of August.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth